BNTX BioNTech Pharma: Multiplikator Forward P/S
BioNTech SE is optimizing vaccine production and delivery by leveraging external manufacturing capacities and outsourced testing. Its proprietary mRNA platform and exclusive alliances with industry behemoths create powerful scientific synergy. A shift in the forward P/S, where the parameter has settled at 7.50, helps assess market expectations amid the reallocation of capital toward the development of innovative cancer treatments.
BioNTech Pharma - rincian analitis lan metrik utama (BNTX)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- statistik nilai buku emiten:
- rincian struktur utang lan likuiditas bisnis:
Utang marang Ekuitas BioNTech SE|BNTX - Rasio utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas BioNTech SE|BNTX - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku BioNTech Pharma|BNTX - Utang jangka dawa|Utang jangka cendhak perusahaan BioNTech|Rasio cepet biontech.de
- rincian asil keuangan lan kelipatan valuasi:
BNTX - Bathi pungkasan|Bathi mangsa ngarep BioNTech SE|BNTX - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep BioNTech Group|BNTX - Kapitalisasi marang bathi resik kanthi nimbang wutah|Pangali EV/EBITDA BioNTech Pharma|BNTX - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) BioNTech|BNTX - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan biontech.de|BNTX - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep BioNTech SE
- indikator volume dodolan lan pendapatan:
Analisis umum perusahaan:BioNTech BNTX
A conservative approach to analyzing BioNTech SE requires comparing market capitalization with expected revenue. This ratio measures the cost per unit of future sales, reflecting market expectations regarding the monetization of mRNA patents and oncology developments. By analyzing the projected P/S multiple, an investor can assess the degree of asset overvaluation amid strict FDA and EMA regulatory oversight, thereby determining the company's investment profile.
Analisis pesaing
Multiplikator Forward P/S ARGX (argenx)|Abivax Pharma (ABVX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ADMA Bio - Multiplikator Forward P/S|PTGX: Rasio rega marang prakiraan pendapatan|IMVT: Multiplikator Forward P/S|KNSA - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Grifols|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Adaptive Biotech ADPT|Rasio rega marang prakiraan pendapatan Celldex (CLDX)|Aurinia Corp - Kapitalisasi marang prakiraan pendapatan|BioCryst - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake VERA (veratx.com)|Dianthus Therapeutics, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pharvaris NV|ABCL: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Tourmaline|PGEN (Precigen, Inc.) - Multiplikator Forward P/S|PHAR: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Zenas Biopharma, Inc. ZBIO|Rasio kapitalisasi marang dodolan sing dikarepake Immunome Bio (IMNM)|Gossamer Bio, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep kalvista.com|SEPN: Multiplikator Forward P/S|PVLA (Pieris Pharma) - Rasio rega marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Savara Corp|Kapitalisasi marang prakiraan pendapatan RIGL (Rigel Corp)|Multiplikator forward rega marang pendapatan ANAB (AnaptysBio, Inc.)|Rasio rega marang pendapatan sing dikarepake ATXS|enGene - Multiplikator forward rega marang pendapatan|RAPT: Kapitalisasi marang prakiraan pendapatan|JBIO - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan ACRS|KYTX: Multiplikator Forward P/S|tizianalifesciences.com - Rega forward marang dodolan|CABA (Cabaletta Bio) - Multiplikator Forward P/S|Multiplikator Forward P/S Ventyx Biosciences Inc.|Rasio rega marang prakiraan pendapatan Theratechnologies Inc (THTX)|AVTX (Avalo Therapeutics Inc) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Eledon Pharmaceuticals ELDN|AGEN - Multiplikator forward rega marang pendapatan|Climb Bio - Multiplikator Forward P/S|ZURA - Multiplikator Forward P/S|ATYR (aTyr) - Multiplikator forward rega marang pendapatan|Adagene Inc. - Rega forward marang dodolan|IMA (ImageneBio) - Multiplikator Forward P/S|Shattuck Therapeutics (STTK) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Equillium, Inc. (EQ)|Multiplikator forward rega marang pendapatan connectbiopharm.com CNTB|Rasio rega marang prakiraan pendapatan Immunic IMUX|ATRA - Multiplikator forward rega marang pendapatan|IFRX: Multiplikator forward rega marang pendapatan|XFOR - Multiplikator Forward P/S|adicetbio.com (ACET) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan CELU|INMB (INmune Bio Corp) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Barinthus Biotherapeutics Corp BRNS|Multiplikator Forward P/S KZR|Rasio rega marang prakiraan pendapatan SABS (sabbiotherapeutics.com)|Multiplikator Forward P/S AKTX (Akari Therapeutics Plc)|Rasio kapitalisasi marang dodolan sing dikarepake Enlivex Therapeutics Ltd (ENLV)|QTTB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep GeoVax Corp|Edesa Biotech, Inc. (EDSA) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan IBIO|Multiplikator forward rega marang pendapatan CARM|XTLB (XTL Biopharmaceuticals Ltd) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S BOLT|HCWB - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S APVO (Aptevo Therapeutics Inc.)|AIM - Multiplikator forward rega marang pendapatan|Aditxt Corp - Multiplikator Forward P/S|Rega forward marang dodolan GRI (GRI Bio Inc)|XRTX (XORTX) - Multiplikator forward rega marang pendapatan|Vyome Therapeutics - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Revelation Biosciences|indaptusrx.com (INDP) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S SCNI|CALI - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S AFMD (Affimed N.V.)|Allakos Inc - Rasio rega marang prakiraan pendapatan|HOOK - Rasio rega marang prakiraan pendapatan|IGMS (IGM Biosciences, Inc.) - Kapitalisasi marang prakiraan pendapatan|ITOS (iTeos Therapeutics, Inc.) - Multiplikator forward rega marang pendapatan|OCEA: Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan TCBP|Kapitalisasi marang prakiraan pendapatan THRD (Third Harmonic Bio Inc)
